NDC properties for NDC 9 0591-2926
NDC item 00591292625
| NDC 9 | 0591-2926 |
|---|---|
| NDC 10 | 0591-2926-25 |
| NDC Item | 00591292625 |
| packaging | 2.5 g in 1 PACKET |
| ANDA | ANDA204570 |
| DCSA | CIII |
| FDA SPL set id | 546325 |
| Labeler | Actavis Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2021-02-12 |
| Marketing status | ACTIVE |
NDC item 00591292630
| NDC 9 | 0591-2926 |
|---|---|
| NDC 10 | 0591-2926-30 |
| NDC Item | 00591292630 |
| packaging | 30 PACKET in 1 CARTON (0591-2926-30) / 2.5 g in 1 PACKET (0591-2926-25) |
| ANDA | ANDA204570 |
| DCSA | CIII |
| FDA SPL set id | 546325 |
| Labeler | Actavis Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2021-02-12 |
| Marketing status | ACTIVE |
NDC item 16714096901
| NDC 9 | 16714-969 |
|---|---|
| NDC 10 | 16714-969-01 |
| NDC Item | 16714096901 |
| packaging | 2.5 g in 1 PACKET |
| ANDA | ANDA205781 |
| DCSA | CIII |
| FDA SPL set id | 775662 |
| Labeler | Northstar Rx LLC |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2019-11-06 |
| Marketing status | ACTIVE |
NDC item 16714096902
| NDC 9 | 16714-969 |
|---|---|
| NDC 10 | 16714-969-02 |
| NDC Item | 16714096902 |
| packaging | 30 PACKET in 1 CARTON (16714-969-02) / 2.5 g in 1 PACKET (16714-969-01) |
| ANDA | ANDA205781 |
| DCSA | CIII |
| FDA SPL set id | 775662 |
| Labeler | Northstar Rx LLC |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2019-11-06 |
| Marketing status | ACTIVE |
NDC item 45802036602
| NDC 9 | 45802-366 |
|---|---|
| NDC 10 | 45802-366-02 |
| NDC Item | 45802036602 |
| packaging | 2.5 g in 1 PACKET |
| ANDA | ANDA205781 |
| DCSA | CIII |
| FDA SPL set id | 784981 |
| Labeler | Padagis Israel Pharmaceuticals Ltd |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2019-06-06 |
| Marketing status | ACTIVE |
NDC item 45802036665
| NDC 9 | 45802-366 |
|---|---|
| NDC 10 | 45802-366-65 |
| NDC Item | 45802036665 |
| packaging | 30 PACKET in 1 CARTON (45802-366-65) / 2.5 g in 1 PACKET (45802-366-02) |
| ANDA | ANDA205781 |
| DCSA | CIII |
| FDA SPL set id | 784981 |
| Labeler | Padagis Israel Pharmaceuticals Ltd |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2019-06-06 |
| Marketing status | ACTIVE |
NDC item 68382036213
| NDC 9 | 68382-362 |
|---|---|
| NDC 10 | 68382-362-13 |
| NDC Item | 68382036213 |
| packaging | 2.5 g in 1 PACKET |
| DCSA | CIII |
| FDA SPL set id | 676429 |
| Labeler | Zydus Pharmaceuticals (USA) Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA AUTHORIZED GENERIC |
| Marketing effective time high | 2021-08-31 |
| Marketing effective time low | 2018-10-12 |
| Marketing status | COMPLETED |
| NDA_AUTHORIZED_GENERIC | NDA022309 |